RecruitingPhase 2NCT07104487

[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease

An Exploratory Study of [18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease

Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

24 participants

Start Date

Mar 18, 2025

Study Type

INTERVENTIONAL

Conditions

Atherosclerosis Cardiovascular Disease Stroke (CVA) or TIA Carotid Artery Plaque Carotid Arteriosclerosis

Summary

This clinical trial aims to evaluate whether \[¹⁸F\]AlF-OC PET/MRI can characterize and quantify inflammation in carotid atherosclerotic plaques. The study will assess if tracer uptake in culprit and non-culprit carotid arteries, measured by standardized uptake values (SUV), is associated with future cerebrovascular events. Specifically, it will examine whether \[¹⁸F\]AlF-OC uptake predicts the risk of recurrent ipsilateral TIA, amaurosis fugax, stroke, or other vascular complications. Participants will undergo \[¹⁸F\]AlF-OC PET/MRI and will be followed via telephone interviews at 90 days, 1 year, and 3 years after their initial stroke or TIA.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called [18F]AlF-OC for people with atherosclerosis cardiovascular disease, carotid arteriosclerosis, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]AlF-OC

Participants received a single intravenous (IV) bolus injection of 4 MBq/kg \[¹⁸F\]AlF-OC (Al¹⁸F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide), followed by a flush with 0.9% NaCl.